Science policy affects a broad range of issues, ranging from data sharing and gene editing, to intellectual property and regulation.
Everyone should have access to the life-changing benefits of medicines and other healthcare interventions, like vaccines, diagnostics and therapies.
We want the research we fund – like publications, data, software and materials – to be open and accessible, so it can have the greatest possible impact.
We're working with the UK government and others to achieve a Brexit settlement that allows research to thrive in the UK and Europe.
Patient data is hugely valuable for research. But the value of that data can only be unlocked if concerns about patient privacy are taken seriously.
Good research practice is one of the foundations of high-quality research.
Government investment plays an important part in supporting scientific excellence in the UK.
Research is an essential part of being ready for and responding to public health emergencies.
The recommendations set out in the review mark one of the first steps towards making sure that promising drugs, devices, diagnostics and digital products are adopted quickly across the NHS.
Gene editing allows scientists to change gene sequences by adding, replacing or removing sections of DNA.
The new European Data Protection Regulation was agreed in April 2016 and will take effect from May 2018.
The European Commission has published a proposal to update EU copyright law so that it applies equally across Europe and is fit for purpose in the 21st century.
Almost every major breakthrough in human and veterinary medicine has depended on the use of animals in the research, development or testing of new therapies.
Mitochondrial donation is an IVF technique that gives families affected by mitochondrial disease the chance of having healthy children.
The European Union is revising regulations governing the manufacture and sale of medical devices.
The Expert Advisory Group on Data Access promoted good working practices, consistent governance and transparent decision making for managing and using data from cohort studies.
A briefing on the economic benefits of musculoskeletal disease research in the UK.
Together with the Royal Society, we asked individuals and organisations from across the UK and EU for their recommendations about how future research and innovation partnerships should work after Brexit.
A synthesis of the existing evidence on the EU-UK relationship on research and innovation, produced by the Royal Society.
Briefings and responses
House of Commons Science and Technology Committee
Migratory Advisory Committee
House of Lords